Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 8:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 1,706 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS) Clear all

Conditions: HIV-1 Infection
Interventions: Vorinostat, AGS-004; Drug · Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 64 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: HIV, Sexually Transmitted Infections
Interventions: CNU Intervention, WP Intervention; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 424 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Pneumococcal Infections
Interventions: V114, Prevnar 13™, PNEUMOVAX™23; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 4
States / cities: Orlando, Florida • West Palm Beach, Florida • Houston, Texas

Conditions: HIV Infection, Hepatitis C Infection, Fibrosis, Inflammation
Interventions: Not listed
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Anal Neoplasm
Interventions: VGX-3100, CELLECTRA™ 5PSP; Biological · Device
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: HIV Infections
Interventions: HST-NEETs; Biological
Lead sponsor: Catherine Bollard; Other
Eligibility: 18 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Washington D.C., District of Columbia

Conditions: HIV Infections, Cytopenias
Interventions: Sargramostim; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years to 50 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Los Angeles, California • Boston, Massachusetts

Conditions: Human Papilloma Virus, Human Papilloma Virus Vaccine
Interventions: CDC 4 Pillars Program; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Albany, Georgia • Atlanta, Georgia • Lithonia, Georgia

Conditions: HIV Infection, Inflammation, Cardiovascular Disease, HIV Infections
Interventions: raltegravir, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV -1 Infection
Interventions: Live Biotherapeutic Product L. jensenii 1153-1666, Placebo; Drug
Lead sponsor: Craig Cohen, MD, MPH; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infection
Interventions: Linkage-to-Care Component: Financial Incentive (FI), Linkage-to-Care Component: Standard of Care (SOC), Viral Suppression Component: FI, Viral Suppression Component: SOC, Prevention for Positives Component: Counseling and SOC, Prevention for Positives Component: SOC; Behavioral
Lead sponsor: HIV Prevention Trials Network; Network
Eligibility: Not listed
Enrollment: 18,442 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • New York, New York

Conditions: HIV Infections, HIV Wasting Syndrome
Interventions: Testosterone enanthate, Megestrol acetate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 21
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more

Conditions: Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma
Interventions: Not listed
Lead sponsor: West Virginia University; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: HIV Infection
Interventions: Polyphenon E, Placebo; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Perinatal HIV Infection, Cardiac Fibrosis, Cardiac Inflammation
Interventions: Cardiac MRI; Diagnostic Test
Lead sponsor: Duke University; Other
Eligibility: 20 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: HIV Infections, Sexually Transmitted Diseases, Bacterial, Hepatitis C, Substance Use Disorders
Interventions: Mobile Enhanced Prevention Support, Usual Care plus Customized Referrals; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 233 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: Los Angeles, California • Santa Fe Springs, California

Conditions: Human Immunodeficiency Virus
Interventions: Busulfan, Cal-1 modified HSPC, Cal-1 modified CD4+ T lymphocytes; Drug · Biological
Lead sponsor: Calimmune, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Los Angeles, California • San Francisco, California

Conditions: HIV Infection
Interventions: Vitamin D3 50,000 IU, Vitamin D3 placebo; Dietary Supplement
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 16 Years to 24 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 16
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 11 more

Conditions: HIV Infections, Syphilis Infection
Interventions: Chembio HIV/Syphilis rapid Point of Care (POC) test, Laboratory-based HIV and syphilis testing; Diagnostic Test
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 14 Years to 45 Years · Female only
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hiv, Healthy
Interventions: Observational; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 25 Years to 50 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Human Immunodeficiency Virus, Sexually Transmitted Infections, Anxiety, Depression, Substance Use Disorders
Interventions: Project PRIDE; Behavioral
Lead sponsor: University of Houston; Other
Eligibility: 18 Years to 25 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Nonneoplastic Condition, Precancerous Condition
Interventions: DNA analysis, polymerase chain reaction, fluorescence activated cell sorting, questionnaire administration, study of socioeconomic and demographic variables, study of high risk factors; Genetic · Other · Procedure
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older · Male only
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV-1 Infection
Interventions: Pitavastatin, Placebos; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 40 Years to 75 Years
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 30
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more

Conditions: HIV
Interventions: MRI, L-NMMA, Acetylcholine; Procedure · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection

Connect 'n Unite: Couples-Based HIV/STI Prevention for Drug-Involved, Black MSM

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)

Study on Immunopathogenesis in HIV and Hepatitis C Coinfection

VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2

HIV-1 Specific T -Cells (HST-NEETs) for HIV-Infected Individuals

An Open Label Phase I Study of Subcutaneously Administered Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia

Advancing HPV Vaccination Among HIV Positive Adults: The CHAMPS Study

Effect of Raltegravir on Endothelial Function in HIV-Infected Patients

Safety Study of MucoCept-CVN

Evaluating Methods to Increase HIV Testing, Access to HIV Care, and HIV Prevention Strategies

A Study of Megestrol Acetate Alone or in Combination With Testosterone Enanthate Drug in the Treatment of HIV-Associated Weight Loss

Prospective Study of Lymphoproliferative Diseases

Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals

Immune Correlates of Cardiac Structure and Function

Mobile Enhanced Prevention Support for People Leaving Jail

Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection

Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART

Implementation of an Opt-Out Testing and Rapid Diagnostic Strategy for Syphilis and HIV in Pregnant Patients Presenting to the Emergency Department

Mapping the Human HIV Chronobiome

Project PRIDE (Promoting Resilience In Discriminatory Environments)

Human Papilloma Virus Infection in HIV-Positive Indian Men Who Have Sex With Men

PREPARE (A5361s) Ancillary Study of REPRIEVE (A5332)

Sildenafil to Treat HIV-Associated Pulmonary Hypertension